🇺🇸 FDA
Patent

US 9446028

Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome

granted A61KA61K31/437A61K9/0019

Quick answer

US patent 9446028 (Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome) held by OVID THERAPEUTICS INC. expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/437, A61K9/0019, A61K9/0053, A61K9/7023